Patents by Inventor Joerg Thomas Regula

Joerg Thomas Regula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12030952
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: July 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20240141044
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 6, 2023
    Publication date: May 2, 2024
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Patent number: 11958912
    Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 16, 2024
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joerg Moelleken, Michael Molhoj, Christian Gassner, Manuel Endesfelder, Joerg-Thomas Regula
  • Publication number: 20240077495
    Abstract: Herein is reported the use of a binding assay of a bivalent, bispecific antibody that has the smaller kD value (dissociation constant) for the interaction with its antigen for the immobilization of the bivalent, bispecific antibody to a solid surface for the determination of the biological activity of the bivalent, bispecific antibody.
    Type: Application
    Filed: April 4, 2023
    Publication date: March 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Apollon Papadimitriou, Joerg Thomas Regula, Hubert Kettenberger, Joerg Moelleken, Christian Gassner
  • Publication number: 20240010720
    Abstract: The invention is based on the surprising finding of antibodies that bind to an immunoglobulin-like (Ig) domain of the extra cellular domain (ECD) of IGSF11 (VSIG3) can also inhibit the interaction between IGSF11 and IGSF11 receptors such as VSIR (VISTA), the inhibition of such interaction can provide products, compositions and methods for treating diseases using antigen binding proteins targeting an Ig domain of IGSF11-ECD, including those being inhibitors of IGSF11-interaction with VSIR. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of cell-mediated immune responses, and/or to kill such cells and/or methods for treating proliferative diseases, using an IGSF11 inhibitor such as an antibody binding to an Ig domain of IGSF11-ECD, as well as certain related aspects including detection, diagnostic and screening methods.
    Type: Application
    Filed: July 6, 2020
    Publication date: January 11, 2024
    Applicant: iOmx Therapeutics AG
    Inventors: Jonas ZANTOW, Stefanie URLINGER, Joerg Thomas REGULA, Sabrina GENSSLER, Maximilian AIGNER, Simone BRAENDLE, Stefan BISSINGER, Tillman MICHELS, Nisit KHANDELWAL
  • Publication number: 20230399391
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 5, 2023
    Publication date: December 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine lmhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Publication number: 20230365702
    Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: April 10, 2023
    Publication date: November 16, 2023
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11787868
    Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: October 17, 2023
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20230287118
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: September 14, 2023
    Inventors: Oliver AST, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Publication number: 20230212277
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 23, 2022
    Publication date: July 6, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Patent number: 11673945
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
  • Patent number: 11603411
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20230068801
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: April 28, 2022
    Publication date: March 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER
  • Publication number: 20220403027
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: April 1, 2022
    Publication date: December 22, 2022
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Publication number: 20220372138
    Abstract: The invention is based on the surprising finding of antibodies that bind to an immunoglobulin-like (Ig) domain of the extra cellular domain (ECD) of IGSF11 (VSIG3) can also inhibit the interaction between IGSF11 and IGSF11 receptors such as VSIR (VISTA), the inhibition of such interaction can sensitise tumour cells to anti-tumour immune responses. In particular, the invention provides products, compositions and methods for treating diseases using modulators of IGSF11, especially antigen binding proteins targeting an Ig domain of IGSF11-ECD, including those being inhibitors of IGSF11-interaction with VSIR. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of cell-mediated immune responses, and/or to kill such cells and/or methods for treating proliferative diseases, using an IGSF11 inhibitor such as an antibody binding to an Ig domain of IGSF11-ECD, as well as certain related aspects including detection, diagnostic and screening methods.
    Type: Application
    Filed: July 6, 2020
    Publication date: November 24, 2022
    Inventors: Maximilian AIGNER, Stefan BISSINGER, Simone BRAENDLE, Sabrina GENSSLER, Stefanie URLINGER, Nisit KHANDELWAL, Jörg Thomas REGULA, Tillmann MICHELS, Jonas ZANTOW
  • Publication number: 20220363771
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: January 27, 2022
    Publication date: November 17, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Thomas REGULA, Wolfgang SCHAEFER, Michael MOLHOJ, Sabine IMHOF-JUNG, Christian KLEIN
  • Publication number: 20220324955
    Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the fi
    Type: Application
    Filed: May 26, 2022
    Publication date: October 13, 2022
    Inventors: Joerg Thomas Regula, Wolfgang Schaefer, Tilman Schlothauer
  • Publication number: 20220306761
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 29, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • Publication number: 20220259327
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Publication number: 20220259326
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana